Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the (a) accessibility and (b) availability of functional MRI scans.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Functional magnetic resonance imaging (MRI) scans can be taken on standard clinical MRI machines. However, whilst functional MRI requires specialised software to detect blood flow changes, the blood-oxygen-level-dependent signal, and sometimes extra equipment for stimuli, for instance goggles, it uses the same scanner hardware as structural MRI.
We are committed to transforming diagnostic services and will support the National Health Service to increase diagnostic capacity to meet the demand for diagnostic services, including MRI scanners.
The 2025 Spending Review confirmed over £6 billion of additional capital investment over five years across new diagnostic, elective, and urgent care capacity. This includes £600 million in capital funding for diagnostics in 2025/26 to support delivery of the NHS performance standards. This funding will deliver replacement of the oldest MRI scanners in community diagnostic centres and acute hospital settings, as well as delivering MRI acceleration software. Business cases for the locations of these are being considered for approval.
Capital investment will be targeted to locations where it will enable the additional activity required to deliver the return to referral to treatment and cancer constitutional standards promised, as well as considering local levels of deprivation so that investment supports efforts to reduce health inequalities.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase access to healthcare services in rural areas.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government’s 10-Year Health Plan has set out a long-term vision to reform the National Health Service and make it fit for the future. Addressing healthcare inequity is a core focus of the 10-Year Health Plan, to ensure the NHS is there for anyone who needs it whenever they need it.
This includes ending the postcode lottery for cancer patients through introducing new training places targeted at trusts with the biggest workforce gaps, prioritising rural and coastal areas.
There are also a range of adjustments made to integrated care board funding allocations that account for the fact that the costs of providing health care may vary between rural and urban areas. These adjustments specifically support remote or sparsely populated areas.
Asked by: Mike Martin (Liberal Democrat - Tunbridge Wells)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for NHS use; and whether he plans to review the CAR‑T delivery tariff to ensure continued access to treatments.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it can be recommended for routine National Health Service funding following a period of managed access through the Cancer Drugs Fund. NICE’s draft guidance, published in December, does not recommend it as a clinically and cost-effective use of NHS resources. The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients with mantle cell lymphoma will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
The CAR-T delivery tariff reflects the costs which the NHS incurs for delivering CAR-T therapy. The tariff was updated for the start of the 2024/25 financial year following a planned costing review involving all CAR-T providers in England. This enabled the tariff to be updated with the benefit of the significant delivery experience that can be drawn on having first routinely introduced CAR-T in the NHS in 2023. Other than considering an appropriate inflationary uplift on an annual basis, in line with usual practice, there are no plans to further review the tariff at this time. Other CAR-T therapies have been recommended for routine NHS adoption in England by NICE based on an assessment of clinical and cost effectiveness that reflects the existing CAR-T delivery tariff, most recently obecabtagene autoleucel for acute lymphoblastic leukaemia.
Asked by: Lord Moylan (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what treatments exist for those mantle cell lymphoma patients unable to access allogeneic stem cell transplants due to (1) ethnicity, (2) age, and (3) ethnicity and age.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
A number of National Health Service treatment options are available for patients with mantle cell lymphoma, and may include:
- chemotherapy plus rituximab;
- autologous stem cell transplant;
- ibrutinib;
- zanubrutinib;
- brexucabtagene autoleucel, a type of chimeric antigen receptor T-cell therapy; and/or
- supportive care.
None of these treatments are precluded on the basis of ethnicity, age, or a combination of the two, but available options will be dependent on individual clinical circumstances and any prior treatment or treatments received.
Potential treatment options are also currently being appraised by the National Institute for Health and Care Excellence and therefore could be made available within England in the future, subject to positive recommendations on NHS adoption being reached. These are: Acalabrutinib with bendamustine and rituximab; and Ibrutinib with R-CHOP.
Asked by: Lord Freyberg (Crossbench - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what proportion of health technology assessments submitted to the National Institute for Health and Care Excellence in the past five years have related to cancer; and what assessment they have made of the importance of up-to-date national registry data to those evaluations.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In the financial years 2021/22 to 2025/26, to date, the National Institute for Health and Care Excellence (NICE) has made 429 technology appraisal recommendations. Of these appraisals, 218 relate to cancer medicines. The Department has not made any assessment of the importance of an up-to-date national registry on those evaluations. NICE works with companies and wider stakeholders throughout the appraisal process to ensure that its appraisals take into account the available evidence.
Asked by: Lord Freyberg (Crossbench - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what is the current average time from test request to result for tests provided by NHS England's genomic medicine laboratories; and what assessment they have made of the impact of those turnaround times on patient access to appropriate treatment for (1) SOD1 testing in motor neurone disease, (2) germline BRCA1/2 testing in hereditary female cancers, and (3) homologous recombination deficiency testing in breast cancer and ovarian cancer.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In December 2025, the average turnaround time for genomic tests processed through the NHS Genomic Laboratory Hubs were 42 days for the test code which includes SOD1 analysis for motor neuron disease, as well as other clinical indications, 37 to 42 days for germline BRCA1/2 testing, and 22 days for homologous recombination deficiency (HRD) testing for ovarian carcinomas. These are within the national targets of 42 days for the test code which includes SOD1 analysis for motor neuron disease and BRCA1/2 and 28 days for HRD, supporting timely clinical decision‑making. As genomic results directly inform treatment choices for motor neurone disease, hereditary female cancers, and ovarian carcinoma, maintaining these turnaround times is essential to ensuring patients can access appropriate therapies without delay.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of limited fresh-freezing capacity on patients’ access to emerging cancer (a) testing and (b) treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of (a) fresh-freezing, (b) snap-freezing and (c) flash frozen capacity for brain cancer tissue samples across NHS trusts in England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Kim Johnson (Labour - Liverpool Riverside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the funding required to ensure equitable access to tissue-freezing services for cancer patients across England; and whether his Department is taking steps to reduce regional disparities.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues. Individual pathology services maintain their own standard operating procedures (SOPs) for fresh, or snap-freezing, of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support National Health Service trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Neil Hudson (Conservative - Epping Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve access to routine tissue freezing for brain cancer patients in a) Epping Forest and b) England for even access to advanced treatments, diagnostics and research.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
No recent assessment has been made on the adequacy, extent, or capacity of procedures for freezing brain cancer and general cancer tissue samples across National Health Service trusts in Epping Forest or England.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.